60 related articles for article (PubMed ID: 28486273)
21. Induction of cytolytic T lymphocytes by immunization of mice with an adenovirus containing a mouse homolog of the human MAGE-A genes.
Van Pel A; De Plaen E; Duffour MT; Warnier G; Uyttenhove C; Perricaudet M; Boon T
Cancer Immunol Immunother; 2001 Jan; 49(11):593-602. PubMed ID: 11225990
[TBL] [Abstract][Full Text] [Related]
22. Immunopeptidomic Profiling of HLA-A2-Positive Triple Negative Breast Cancer Identifies Potential Immunotherapy Target Antigens.
Ternette N; Olde Nordkamp MJM; Müller J; Anderson AP; Nicastri A; Hill AVS; Kessler BM; Li D
Proteomics; 2018 Jun; 18(12):e1700465. PubMed ID: 29786170
[TBL] [Abstract][Full Text] [Related]
23. Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer.
Bernhard H; Neudorfer J; Gebhard K; Conrad H; Hermann C; Nährig J; Fend F; Weber W; Busch DH; Peschel C
Cancer Immunol Immunother; 2008 Feb; 57(2):271-80. PubMed ID: 17646988
[TBL] [Abstract][Full Text] [Related]
24. Tumor Cells Surviving Exposure to Proton or Photon Radiation Share a Common Immunogenic Modulation Signature, Rendering Them More Sensitive to T Cell-Mediated Killing.
Gameiro SR; Malamas AS; Bernstein MB; Tsang KY; Vassantachart A; Sahoo N; Tailor R; Pidikiti R; Guha CP; Hahn SM; Krishnan S; Hodge JW
Int J Radiat Oncol Biol Phys; 2016 May; 95(1):120-130. PubMed ID: 27084634
[TBL] [Abstract][Full Text] [Related]
25. Emerging roles of the MAGE protein family in stress response pathways.
Florke Gee RR; Chen H; Lee AK; Daly CA; Wilander BA; Fon Tacer K; Potts PR
J Biol Chem; 2020 Nov; 295(47):16121-16155. PubMed ID: 32921631
[TBL] [Abstract][Full Text] [Related]
26. Targeting the Microtubule-Network Rescues CTL Killing Efficiency in Dense 3D Matrices.
Zhao R; Zhou X; Khan ES; Alansary D; Friedmann KS; Yang W; Schwarz EC; Del Campo A; Hoth M; Qu B
Front Immunol; 2021; 12():729820. PubMed ID: 34484240
[TBL] [Abstract][Full Text] [Related]
27. Gene network-based and ensemble modeling-based selection of tumor-associated antigens with a predicted low risk of tissue damage for targeted immunotherapy.
Lischer C; Eberhardt M; Flamann C; Berges J; Güse E; Wessely A; Weich A; Retzlaff J; Dörrie J; Schaft N; Wiesinger M; März J; Schuler-Thurner B; Knorr H; Gupta S; Singh KP; Schuler G; Heppt MV; Koch EAT; van Kleef ND; Freen-van Heeren JJ; Turksma AW; Wolkenhauer O; Hohberger B; Berking C; Bruns H; Vera J
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38724462
[TBL] [Abstract][Full Text] [Related]
28. T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reduces
Inderberg EM; Wälchli S; Myhre MR; Trachsel S; Almåsbak H; Kvalheim G; Gaudernack G
Oncoimmunology; 2017; 6(4):e1302631. PubMed ID: 28507809
[TBL] [Abstract][Full Text] [Related]
29. Targeting one-carbon metabolism for cancer immunotherapy.
Ren X; Wang X; Zheng G; Wang S; Wang Q; Yuan M; Xu T; Xu J; Huang P; Ge M
Clin Transl Med; 2024 Jan; 14(1):e1521. PubMed ID: 38279895
[TBL] [Abstract][Full Text] [Related]
30. Cancer/Testis Antigens as Targets for RNA-Based Anticancer Therapy.
Shim K; Jo H; Jeoung D
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834126
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic Regulation of Immunotherapy Response in Triple-Negative Breast Cancer.
Llinàs-Arias P; Íñiguez-Muñoz S; McCann K; Voorwerk L; Orozco JIJ; Ensenyat-Mendez M; Sesé B; DiNome ML; Marzese DM
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439290
[TBL] [Abstract][Full Text] [Related]
32. MAGE-A11 is activated through TFCP2/ZEB1 binding sites de-methylation as well as histone modification and facilitates ESCC tumor growth.
Liu S; Liu F; Huang W; Gu L; Meng L; Ju Y; Wu Y; Li J; Liu L; Sang M
Oncotarget; 2018 Jan; 9(3):3365-3378. PubMed ID: 29423052
[TBL] [Abstract][Full Text] [Related]
33. MAGE-A11 expression contributes to cisplatin resistance in head and neck cancer.
Hartmann S; Zwick L; Scheurer MJJ; Fuchs AR; Brands RC; Seher A; Böhm H; Kübler AC; Müller-Richter UDA
Clin Oral Investig; 2018 Apr; 22(3):1477-1486. PubMed ID: 29034444
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic modulation combined with PD-1/PD-L1 blockade enhances immunotherapy based on MAGE-A11 antigen-specific CD8+T cells against esophageal carcinoma.
Wu Y; Sang M; Liu F; Zhang J; Li W; Li Z; Gu L; Zheng Y; Li J; Shan B
Carcinogenesis; 2020 Jul; 41(7):894-903. PubMed ID: 32529260
[TBL] [Abstract][Full Text] [Related]
35. Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy.
Graff-Dubois S; Faure O; Gross DA; Alves P; Scardino A; Chouaib S; Lemonnier FA; Kosmatopoulos K
J Immunol; 2002 Jul; 169(1):575-80. PubMed ID: 12077290
[TBL] [Abstract][Full Text] [Related]
36. Induction of antitumor cytotoxic T lymphocytes from the peripheral blood mononuclear cells of cancer patients using HLA-A2-restricted MAGE-3 peptide in vitro.
Fujie T; Tanaka F; Mori M; Takesako K; Sugimachi K; Akiyoshi T
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2425-30. PubMed ID: 9815643
[TBL] [Abstract][Full Text] [Related]
37. PDEF and PDEF-induced proteins as candidate tumor antigens for T cell and antibody-mediated immunotherapy of breast cancer.
Sood AK
Immunol Res; 2010 Mar; 46(1-3):206-15. PubMed ID: 19763888
[TBL] [Abstract][Full Text] [Related]
38. Mimotopes of cytolytic T lymphocytes in cancer immunotherapy.
Chen L
Curr Opin Immunol; 1999 Apr; 11(2):219-22. PubMed ID: 10322156
[TBL] [Abstract][Full Text] [Related]
39. Zebularine Treatment Induces MAGE-A11 Expression and Improves CTL Cytotoxicity Using a Novel Identified HLA-A2-restricted MAGE-A11 Peptide.
Zhang J; Sang M; Gu L; Liu F; Li W; Yin D; Wu Y; Liu S; Huang W; Shan B
J Immunother; 2017; 40(6):211-220. PubMed ID: 28486273
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
